Skip to content
Review

Blinded sample size review for McNemar's test based on primary and surrogate endpoints

Aug 2026 · 0 citations · 14 references
Mathematics

TL;DR

A surrogate-based re-estimation approach that conditions on all possible numbers of primary-endpoint discordant pairs using transition rates from the surrogate to the primary outcome is introduced.

Abstract

We develop blinded sample size re-estimation strategies for McNemar's test based on paired binary primary and secondary short-term surrogate endpoints. The development is motivated by a prospective randomized clinical trial on childhood glaucoma. A conditional power expression for McNemar's test given the primary endpoint at an interim analysis is derived and complemented by a sample size re-estimation rule. We show that this procedure preserves the type I error rate while allowing the second-stage sample size to be chosen to attain a prespecified target power. In the case where for some patients only a short-term surrogate endpoint is available at interim, we introduce a surrogate-based re-estimation approach that conditions on all possible numbers of primary-endpoint discordant pairs using transition rates from the surrogate to the primary outcome. We show how these transition rates can be estimated from data on a subsample for which both surrogate and primary endpoint are available. We derive the resulting surrogate endpoint-based conditional power and sample size rule and illustrate their use with the example of the motivating trial.

View source

Similar papers

Open access Sep 2026

Sample size estimation for a flexible phase II oncology trial design using two dependent endpoints with nested response metrics.

A flexible phase II design framework for two primary endpoints with nested response metrics is developed and the Holm-type and Holm-type designs can reduce the required sample size while maintaining prespecified error-rate and power requirements.

Jiangtao Gou, F. Zhang · 0 citations
Review Oct 2026

Design-Based Validation Method of EHR Algorithms to Address Partial Verification Bias

Electronic health record (EHR) phenotyping algorithms support clinical prediction, observational research, and quality improvement, but manual chart review for gold-standard validation is costly. For algorithms targeting rare outcomes, algorithm-negative patients often greatly outnumber algorithm-positive patients. We...

Rui Tang, M. Blasingame, Lillian Zheng et al. · 0 citations
Preprint Aug 2026

Regression to the Mean-Adjusted Sample-Size Determination for Cutoff-Selected Single-Arm Pre-Post Studies

Studies enrolling participants on the basis of an extreme baseline value are susceptible to regression to the mean (RTM), such that some observed pre-post change is expected even without treatment. Existing methods estimate and decompose RTM retrospectively. We extend this framework to prospective study design by deriv...

Ariel Linden · 0 citations
Open access Aug 2026

reFLASH: A proof-of-concept meta-analytic framework to validate surrogate endpoints in the absence of randomized clinical trial data.

BACKGROUND Within a meta-analytic framework, validating surrogate endpoints traditionally requires individual patient data (IPD) from multiple randomized controlled trials (RCTs). This is rarely feasible in rare and indolent diseases. We propose a proof-of-concept strategy that creates synthetic comparative evidence fr...

C. Bommier, J. Dixon, M. Maurer et al. · 0 citations
Open access Aug 2026

Valid Test for Multi-arm Trials with Generalized Linear Models Under Covariate-adaptive Randomization

A new inference method for conducting multiple-treatment comparisons involving endpoints within the generalized linear model (GLM) framework under covariate-adaptive randomization (CAR) that can effectively control Type I error while potentially improving power.

Guannan Zhai, Fei-Fang Hu · 0 citations
Preprint Aug 2026

From Test Performance to Risk-Based Effect Sizes: A Unified Wald-Type Framework to Design Clinical Validation Studies for Binary and Survival Outcomes

Close-form links from sensitivity, specificity, and disease prevalence to predictive risks, risk contrasts, and Wald-type variance, power, and sample-size formulas for binary and fixed-horizon survival outcomes for binary and fixed-horizon survival outcomes are provided.

Yong-Qi Zhong, A. Hartman, Jing Zhang · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.